Auxogyn, Inc. is focused on advancing the field of reproductive health through its uniquely-combined knowledge of early human developmental biology, advanced computer vision technology and best clinical practices. The company's first product, Early Embryo Viability Assessment (Eeva), provides quantitative information regarding embryo development, to assist IVF clinicians in optimizing the treatment path for their patients undergoing IVF procedures. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, TPG Biotech and Merck Serono Ventures.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/02/12 | $20,000,000 | Series A | ||
| 06/05/12 | $18,000,000 | Series B |
Merck Serono Ventures SR One TPG Biotech | undisclosed |
